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Abstract 
Background: Health-related quality-of-life is an important outcome measure in patients with 
colorectal cancer. Comparison with normative data is increasingly undertaken to assess the 
additional impact of colorectal cancer on health-related quality of life.  
Objective: This review aimed to critically appraise methodological details and reporting 
characteristics of comparative studies evaluating differences in health-related quality-of-life 
between patients and controls. 
Data sources: A systematic search of English-language literature published between January 
1985 and May 2014 was conducted through a database search of Pubmed, Web of Science, 
Embase, and Medline. 
Study Selection: Comparative studies reporting health-related quality-of-life outcomes 
among colorectal cancer patients and controls.  
Main Outcome Measures: Methodological and reporting quality per comparison study was 
evaluated on a 11-item methodological checklist proposed by Efficace and a set of criteria 
pre-determined by reviewers. 
Results: Thirty-one comparative studies involving >10,000 patients and >10,000 controls 
were included. Twenty-three studies (74.2%) originated from European countries, with the 
largest number from Netherland (n=6). Twenty-eight studies (90.3%) compared 
health-related quality-of-life of patients with normative data published elsewhere, while the 
remaining recruited a group of colorectal cancer patients and a group of control patients 
within the same studies. The EORTC QLQ-C30 was the most extensively used instrument 
(n=16; 51.6%). Eight studies (25.8%) were classified as “probably robust” for clinical 
decision making according to the Efficace’s standard methodological checklist. Our further 
quality assessment revealed the lack of scores differences reported (61.3%), contemporary 
comparisons (36.7%), statistical significance tested (38.7%) and matching of control group 
(58.1%), possibly leading to inappropriate control groups for fair comparisons. 
Limitations: Meta-analysis of differences between the two groups was not available. 
Conclusions: One-fourth of comparative studies evaluating health-related quality-of-life of 
colorectal cancer generally achieved high-quality in reporting characteristics and 
methodological details. Future studies are encouraged to undertake health-related 
quality-of-life measurement and adhere with methodological checklist when compared to 
controls.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Running title: Quality of CRC HRQOL comparative studies 
3 
Keywords: systematic review; comparative study; colorectal cancer; quality of life; 
normative   
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Running title: Quality of CRC HRQOL comparative studies 
4 
Manuscript Text 
Introduction 
 
Colorectal cancer (CRC) is one of the commonest cancers and leading cause of cancer 
deaths worldwide1. Due to the emerging treatment therapies for CRC, significant group of 
CRC patients survived with prolonged life expectancy2, whose health-related quality of life 
(HRQOL) outcomes were of interest to the clinicians and decision-makers for the 
development of optimal treatment strategies inducing preservation of HRQOL3. Furthermore, 
the importance of incorporating HRQOL assessments in oncological clinical trials has been 
well recognized in comparative effectiveness research to aid in clinical practice and decision 
making4. 
 
Comparisons with published normative data are undertaken to assess the additional 
impact of cancer and cancer treatment on HRQOL scores5, 6, given the co-existence of 
chronic conditions affecting HRQOL likely. Such comparison is important because 
norm-based comparison allows for quantifying the extent of departures from the norm, and 
facilitating interpretation of the clinical importance of HRQOL scores. With reference to 
country-specific normative data, HRQOL of CRC patients were increasingly compared with 
that of non-CRC control group as an indication of the HRQOL restriction to CRC patients. 
Most studies reported HRQOL outcomes comparisons between the CRC and non-CRC 
control groups with reference to country-specific normative data. Findings from a systematic 
review of ten HRQOL studies among long-term CRC survivors7 concluded that CRC patients 
appeared to have comparable psychological aspect of HRQOL but slightly lower physical 
aspect of HRQOL than available normative data. Of note, the methodological standards and 
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normative data for such HRQOL comparisons varied across studies7, 8, hampering the value 
and importance of clinical interpretation.  
 
In spite of numerous studies available over the past two decades, there has been an 
increased concern on the methodological and reporting quality of HRQOL studies in clinical 
trials involving CRC patients. A 11-item checklist proposed by Efficace et al.9 has been 
widely applicable to evaluate the quality of HRQOL reporting in oncological clinical trials. 
Particularly for CRC studies, systematic review10 identified methodological shortcomings of 
thirty-one randomized controlled trials measuring HRQOL as primary or secondary endpoints, 
particularly addressing the lack of baseline compliance and missing data reported in a 
majority of studies. However, evidence on detailed methodological critique of quality and 
reporting characteristics of comparative studies that assessed HRQOL differences between 
groups is limited. The purpose of this study was to conduct a systematic review of the 
methodological quality of comparative studies that compared HRQOL between CRC and 
control groups by either generic or cancer-specific instruments, including assessment of the 
extent to which the specific domains of HRQOL of CRC patients was significant different 
from that of healthy controls. 
  
Methods 
 
Search Engine and Strategy 
Systematic literature search was conducted on May 2014 in databases of PubMed, 
Web of Science using Web of Knowledge platform, Embase and MEDLINE using OVID 
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searching platform, to identify studies that investigated the HRQOL of colorectal neoplasm 
patients. The Medical Subject Heading (MESH) ‘quality of life’ was combined with ‘colon 
neoplasm’, ‘colon cancer’, ‘rectal cancer’, ‘rectal neoplasm’ and ‘colorectal cancer’. Studies 
were limited to English language, and the years between January 1985 and March 2014. 
Electronic search strategy in each electronic database is showed in Appendix, and has been 
adopted in one previous systematic review11. No additional hand search was done.  
 
After the initial check for duplicated articles, the titles and abstracts of remaining 
articles were screened to rule out the introductories, editorials, letters, commentaries, study 
protocols, case reports, pure literature reviews and meta-analyses, conference proceedings, 
past and current clinical guidelines and recommendations. Selected articles were further 
screened with full texts. The eligibility criteria of studies were 1) to involve original articles, 
2) to measure HRQOL using standardized instruments with items rating on point Likert 
scales or on linear analogue scales, and 3) to compare at least one HRQOL outcome between 
CRC patients and the general population/healthy controls. Articles without available full-text 
were excluded. Articles were also excluded if no abstract and full text available. When there 
were multiple reports of studies using the same sample, the most updated publication of a 
study was included.  
Two reviewers (CW and CJ) independently screened the eligibility criteria of study 
titles, abstracts, and selected full-texts of the studies retrieved by the literature search. Thus, 
assessment of the quality in eligible studies was performed by two reviewers independently 
(CW and CJ). Disagreements regarding the procedures of database search, study selection 
and eligibility were resolved by discussion. 
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Data Extraction 
Study characteristics including first author, year of publication, country of origin, 
study design, population, sample size, demographics of CRC patients and non-CRC control 
population, response rate, HRQOL instruments, and HRQOL outcomes of eligible studies 
were independently extracted by two reviewers (CW and CJ).  
 
Methodological and Reporting Quality Assessment 
Each of the studies was evaluated using the ‘‘Minimum Standard Checklist for 
Evaluating HRQOL Outcomes in Cancer Clinical Trials”12 to access the HRQOL trial quality. 
The checklist consisted of 11 items grouped into four key categories related to the HRQOL 
assessment: conceptual, measurement, methodology and interpretation. This 11-item 
checklist was designed to have a dichotomous answer (yes / no): one mark for ‘yes’ (giving a 
score of 1) and zero mark for ‘no’ (giving a score of 0). Each study was classified into one of 
the following three descriptive categories: “very limited” (with a score between 0 and 4), 
“limited” (with a score between 5 and 7) and “probably robust” (with a score between 8 and 
11 and with three mandatory items of the checklist: baseline compliance, psychometric 
properties reported and missing data documented)12. As a result, studies having a score of 8 
or above but not possessing those three mandatory items were regarded as “limited”. This 
checklist provided a general guideline for addressing the basic and essential issues a study 
should possess in order to have convincing and significant outcomes in the assessment 
methodology. 
 
Besides, authors (CW and CJ) reached consensus on which further quality assessment 
should be evaluated in comparative studies reporting HRQOL differences between CRC 
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patients and controls. A further quality assessment consists of five pre-defined quality 
assessment criteria: 1) Comparing with their populations: CRC and control groups should 
come from an identical source population; 2) Contemporary comparisons: both groups should 
be enrolled during the same time period of within 5 years; 3) General population: as source of 
the comparison group; 4) Matched comparison group: minimizing confounding factors that 
could introduce bias of differences between the CRC and control groups; 5) Reporting and 
presentation of results: results of CRC group, comparison group and the difference between 
groups should be reported and the statistical significance between groups should be tested. 
For each study, every single quality criterion was rated as “Yes” or “No” if the criterion was 
met or not respectively.  
 
Results 
 
Figure 1 lists the process of literature identification, screening for eligibility, and 
selection of studies during the literature search presented in a Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. The literature search was 
completed in June 2014 and identified a total of 7,553 potentially relevant studies (PubMed: 
1,349; Web of Science: 2,318; MEDLINE: 1,735; and Embase: 2,151) that met the searching 
criteria in four bibliographic databases. Abstract screening removed the duplicated articles (n 
= 3,332), non-original articles (n = 1,439), and articles not related to CRC patients (n = 1,346) 
and non-comparative studies (n = 1,401). The full-text content of 35 studies was reviewed for 
eligibility. To exclude ineligible studies due to the use of non-standardized HRQOL 
instrument (n=1) and no general population/healthy controls for comparisons (n=3), the 
full-text articles of all eligible studies (n=31) were included. The earliest comparative study 
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that assessed the difference in HRQOL between CRC patients and controls was published in 
2003. 
 
Demographics and trial design characteristics 
Thirty-one included studies compared various aspects of HRQOL in patients with 
CRC with general population or healthy controls. Three-fourth (n=23; 74.2%) of studies13-36  
originated from European countries, particularly in Netherland (n=6; 19.4%)16, 23, 28-31, 
Germany (n=4; 12.9%)13, 14, 20, 21, Italy (n=4; 12.9%)17, 24, 25, 27 and Scandinavia (n=3; 9.7%). 
The remainders were originated from the US (n=5; 16.1%)6, 22, 37-39, Australia (n=2; 6.5%)40, 
41, and Asia (n=1; 3.2%)42. Twenty-eight studies (90.3%) collected a sample of CRC patients 
and compared them to normative data published elsewhere13-31, 33-42, while the remaining 
minority recruited a group of CRC patients and a group of healthy control subjects within the 
same studies. A summary of these 31 comparative studies is presented in Table 1. 
 
Table 2 shows the general characteristics and available normative data of the 
standardized validated HRQOL instruments identified in comparative studies. The European 
Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 
(EORTC QLQ-C30) was the most extensively used HRQOL instrument, which was used in 
over half (n=16; 51.6%) of the studies 13-15, 18-22, 24-26, 31, 32, 34-36. The European Organisation 
for Research and Treatment of Cancer Colorectal Cancer Specific Quality-of-Life 
Questionnaire module (EORTC QLQ-CR38) was also applied in 13 (43.3%) studies 14, 16, 19, 
22-26, 29-32, 35. Six non-cancer-specific HRQOL instruments such as EuroQoL 5-dimension 
(EQ-5D), SF-36, SF-12, SF-6D, Psychological General Well-Being Index (PGWBI), Hospital 
Anxiety and Depression Scale (HADS) were identified for HRQOL comparisons in 
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comparative studies. Aforementioned eight instruments were standardized and validated 
HRQOL instruments, in which those translations are available in many languages. Two 
studies34, 42 reported the HRQOL measured by Functional Assessment of Cancer 
Therapy-colorectal (FACT-C) instrument but normative values of FACT-C instrument were 
not available for comparisons.  
 
Overview of HRQOL assessment methodology and methods of analysis 
In Table 3, the results of the HRQOL assessment methodology and methods of 
analysis are summarized in four major categories: conceptual, measurement, methodology, 
and interpretation, according to the “Minimum Standard Checklist for Evaluating HRQOL 
Outcomes in Cancer Clinical Trials”12. Methodological limitations were identified in several 
aspects of the overall process of HRQOL assessment, particularly in terms of the conceptual, 
methodology, and interpretation. 
 
Conceptual 
In the conceptual criteria, our review figured out a poor reporting of details about the 
priori hypothesis and rationale for selecting a specific HRQOL measure and instrument 
administration. Only one (3.2%) out of 31 studies had a priori hypothesis stated 29 and 35.5% 
(n=11) of the studies provided a rationale for selecting the specific HRQOL instrument 13, 14, 
17, 19, 20, 22, 26, 27, 32, 34, 40. 
 
Measurement 
In terms of measurement, although 38.7% (n=12) of the reports did not verify the 
cultural validity of the study 13, 14, 18-22, 24, 25, 32, 35, 36, all reports except one (96.7%) covered 
adequate HRQOL domains and reported psychometric properties relevant for comparison 6, 
13-42. Thus, there were no major limitations regarding to the aspect of measurement. 
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Methodology 
In our review, 93.5% (n=29) of the included studies had the documentation of timing 
assessment for analysis 6, 13-17, 19-38, 40-42. 87.1% (n=27) of the studies reported the instrument 
administration and baseline compliance 6, 13-42. However, 64.5% (n=20) of the studies did not 
provide any details about HRQOL missing data during the course of analysis 6, 15, 17, 18, 23-25, 
27-31, 33, 35, 37-42. This led to the loss of clinically significant differences due to reduced number 
of observations.  
 
Interpretation 
All of the studies (100%) had adequate presentation and discussion of results in 
general6, 13-42 but ten reports (32.3%) did not provide the clinical significance for analysis 17, 23, 
31-34, 36, 37, 40, 42 which might limit the clear understanding of results and clinical relevance of 
HRQOL changes.  
 
Overview of HRQOL trial quality and treatment recommendation on patient’s HRQOL 
Based on the minimum standard checklist score in Table 4, only one study (3.2%) was 
classified as very limited 35 and 71.0% (n = 22) were classified as limited 6, 15, 17, 18, 21, 23-25, 
27-33, 36-42 while eight studies (25.8%) were classified as “probably robust” for clinical 
decision making13, 14, 16, 19, 20, 22, 26, 34. These studies demonstrated excellent examples for the 
implementation of HRQOL assessment of patients to thoroughly evaluate the overall 
effectiveness of treatment. 
 
Further quality assessment 
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Table 5 depicts the further quality assessments of included studies. Based on five 
pre-defined quality assessment criteria, our study reviewed the poor reporting of result, 
comparison and matching of the patients groups. For the aspects of result and comparison, 
61.3% (n=19) did not have the results of difference between groups reported 14, 16, 17, 21, 22, 25, 26, 
28, 30-35, 37-41 and 36.7% (n=11) were not contemporary comparisons (no. of years > 5) 17, 20, 22, 
24-27, 33-35, 39. 38.7% (n=12) of the papers did not have the results of statistical significance 
tested 12-14, 21, 22, 24, 25, 34, 35, 37, 38, 41 while only 54.8% (n=17) were tested by univariate analysis 
6, 15-20, 23, 26, 27, 29-33, 40, 42 and 6.5% (n=2) were tested by both univariate and multivariate 
analysis 6, 13-35, 37-42. For the matching method, 58.1% (n=18) of studies did not give matching 
criteria and perform matching to identify comparison group 13, 14, 17, 19-22, 26, 27, 32-35, 37-41. 16.7% 
(n=5) did not use population within the same countries as controls to compare 22, 24-26, 35 and 
6.7% (n=2) did not adapt representative general population as source of comparison group6, 
32. 
 
Normative Comparisons 
 
Norms for cancer-specific HRQOL instrument QLQ-C30, which was used in about 
half (n=15; 48.4%) of the studies13-15, 18-22, 24-26, 31, 32, 35, 36, have been obtained from the 
general population in German43, Norway44, Netherland45, Austria46, Sweden47, and France15. 
Published normative data of QLQ-C30 were available in the general adult population after 
matching for age and sex 15, 18, 24, 25, 31, 36 and different aspects such as CRC patients after 
diagnosis 13-15, 20, CRC patients after surgery 21, 31, 32, 34, 36, rectal cancer patients following 
diagnosis 19, 26 and rectal cancer patients following surgery 22, 24, 25, 31, 35. Moreover, reference 
data from the QLQ-C30 in a sample of 3000 adults from Norwegian general population 
provided comparison with rectal cancer patients during radiotherapy 19 or rectal cancer 
survivors 26. Dutch normative data of QLQ-C30 in age- and sex-matched general population 
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were compared with random samples of Eindhoven Cancer Registry31. Besides, norms for 
another cancer-specific HRQOL instrument QLQ-CR38, which was also found in 5 (16.1%) 
studies16, 23, 29-31, have been obtained from the general population in Netherland45 for 
comparisons. Only one study recruited the healthy controls through random sampling in the 
general population32 and tested the control group against the CRC patients after surgery. 
 
Norms for generic HRQOL instruments are also available in multiple countries45, 48-55. 
General population norms for SF-36 Health Survey was compared with HRQOL of CRC 
patients in Netherland23, 29, 30, France15, Australia41, Italy17, Finland33 and the US6, 37, 38. 
Comparisons with general population norms for SF-12 were utilized in UK34, Australia40 and 
Hong Kong42. The HADS score of CRC patients were compared to the UK50 and Dutch28 
general population. The PGWBI, EQ-5D and SF-6D scores were used in one study in Italy 27, 
in UK and in the US39, respectively. 
 
Compared to the normative data from the general population of Italy 24, 25, Germany 13, 
14, 21, Norway 19, Austria 18 and Poland 35, colorectal cancer patients had worse scores in most 
of functioning and symptom scales measured by QLQ-C30. Cancer survivors had 
significantly lower physical component summary (PCS) score compared to the Australian 
general population 41 and the United Kingdom population with an interval of age 65-74 34. 
Inconsistent results were observed in the US population when the generic and cancer-specific 
HRQOL of general population were similar to that of CRC patients 22, 37, 38 but SF-6D score 
norms ranging from 0.76 to 0.80 were higher than that with 0.69 for permanent stoma and 
0.73 for anastomses among CRC survivors 39. Conversely, older CRC survivors reported 
better compared to the general population in Germany 20 and Finland 33 but younger survivors 
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conversely reported worse. The HRQOL of rectal cancer survivors who have completed 
treatment regimen for more than two years or ten years were higher than that of the general 
population from France26 and Netherlands29, 30, respectively. In another French 
population-based study, cancer survivors reported worse social functioning and more diarrhea 
symptoms at five years after diagnosis compared to the healthy control group 15. Healthy 
controls had significantly better results in functional and symptom scales of QLQ-C30 than 
patients with CRC in Bosnia32 and Austria18. 
 
For QLQ-CR38, there were almost no comparisons in those studies between the CRC 
group and control group except one study 32. CRC patients had worse scores in most of scales 
measured by QLQ-CR38 compared to healthy controls. For SF-12, CRC patients had lower 
PCS but higher mental component summary (MCS) scores compared to the norms of their 
respective countries in Australia, UK and Hong Kong34, 40, 42. For SF-36, Italian patients with 
colorectal cancer had lower HRQOL in reference to bodily pain, social functioning and 
general health measured than that of general population17. For Australian rectal cancer 
patients, they had lower PCS but similar MCS to that of general population 41 while there 
were no big difference between the CRC survivors group and control group for the American 
female patients 37, 38. For PGWBI, population-based reference data was collected in the Italian 
general population as control group to compare with rectal cancer survivors who reported 
better scores on all PGWBI scales except for self-control scale 27. 
 
Discussions 
In this systematic review, we summarized and appraised the methodological and 
reporting quality of 31 studies that compared the HRQOL between CRC patients and controls, 
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15 
which provided information on the additional impact of CRC on HRQOL. The results have 
shown that there were only 8 studies (25.8%) considered as “probably robust” regarding the 
methodological and reporting quality of HRQOL comparisons, hampering the informing 
clinical practice and decision making.  
 
This review detected several drawbacks of current studies reporting HRQOL comparisons 
between CRC and control groups. First, there is a disparity of the HRQOL instrument used. 
High-quality studies were more likely to measure HRQOL using the EORTC QLQ-C30 
instrument in conjunction with QLQ-CR38 instrument while several studies only used 
generic HRQOL instruments to compare the HRQOL between the CRC and control groups 
(references only use generic HRQOL). It is more informative to combine both generic and 
specific HRQOL instrument in comparing the HRQOL between the CRC and control groups 
because generic instruments of HRQOL can be used to compare HRQOL over a broad 
spectrum of diseases, as well as general population, and was more responsive to detect 
changes in social domain than colorectal-specific HRQOL instrument56. However, only 5 
studies used both generic and specific HRQOL instruments based on the results of our 
systematic review. Secondly, almost 40% of the included studies used HRQOL instrument 
that has not been culturally verified. It is important to choose a well-tested HRQOL measure 
in certain culture, as it is culture-dependent57. 
 
This review underlined the importance of establishing an appropriate control group for fair 
comparison. Of the 31 included studies, only three studies recruited the CRC patients and 
healthy controls within the same studies15, 18, 32. Some studies even compare reference data 
from different populations, which may not accurately reflect the additional impact of CRC on 
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16 
HRQOL compared to the controls in the same country. Since HRQOL is always dependent 
on age and sex, comparison between CRC patients and the control group should match with 
age and sex, or adjust for multiple covariates using propensity score. However, over 60% of 
the studies did not performed matching strategy to identify the controls. Another issue of the 
control group is relevant to the non-contemporary comparison, which means that the 
difference of the recruitment period between CRC group and the control group is over 5 
years.  
 
Statistical significance is useful in interpreting the data to be accounted for fluctuations by 
chance, and thus does not necessarily imply the clinical significance. A difference that is 
statistically different may have little or even no importance in the realm of health care and 
health decision-making. In this systematic review, ten comparative studies (32.3%) did not 
provide the clinical significance for analysis 17, 23, 31-34, 36, 37, 40, 42, which may hamper the 
clinical meaningfulness based on the results. Clinical significance of HRQOL scores was 
determined by two main approaches. For those studies interpreting whether changes were 
considered as clinical significance, a half-standard deviation approach58, corresponding to 
Cohen’s medium effect size, was adopted6, 16, 28-30 for detecting clinically important 
difference of HRQOL scores. In comparative studies13-15, 18-20, 22, 24, 25 administering EORTC 
instruments, scores difference of at least 10 absolute points is interpreted as a clinically 
important difference according to Osoba et al59.  
 
Priori hypothesis and rational for selection a HRQOL instrument are lacking in most of the 
included studies. As the priori hypothesis is the key prerequisite for deciding which HRQOL 
instrument to be used, the lack of such information may lead to spurious positive results 
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because of the multiple tests in comparing different HRQOL domains between the CRC and 
control groups.  
 
Limitations of this review should be noted. First, methodological quality assessment relied on 
the information reported in published articles which may be shortened subject to the editorial 
and reviewers’ request. Results of published articles may be partially reported. Further 
eta-analysis of differences between the two groups was not available based on HRQOL point 
estimate reported in published articles. 
 
Conclusions 
In conclusion, this review showed that one-fourth of comparative studies generally achieved 
high-quality in reporting characteristics and methodological details. HRQOL is increasingly 
used to complement outcomes of CRC patients, but our systematic review noted that only 8 
out of 31 studies met the methodological criteria as probably robust for clinical decision 
making according to the Minimum Standard Checklist for Evaluating HRQOL Outcomes in 
Cancer Clinical Trials. Researchers should pay careful attention to the HRQOL instrument 
standardization with a priori hypothesis, and to choose a comparable control group with 
similar culture background recruited at a similar time point. Future studies investigating the 
impact of CRC on HRQOL are encouraged to undertake HRQOL measurement and adhere 
with methodological checklist and further pre-defined assessment criteria. 
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Table 1. Study Characteristics of 31 Eligible Studies 
        Target Population   Sample Size Age (year) Male (%)   
First 
Author 
Year of 
Publication 
Country 
of origin 
Study design of 
CRC data 
CRC Trajectory 
Stage of CRC 
Compared with Response 
rate 
CRC non-C
RC 
CRC Non-CRC CRC Non-C
RC 
HRQOL 
instrument 
Arndt 
200413 
2004 Germany Prospective CRC 1 Year After 
Diagnosis 
German general 
population43 
81.7% 309 2028 Mean 65.1 ± 
9.4 (18–80) 
Mean 66.0 ± 
11.6 (16–92) 
56.3% 43.8% EORTC 
QLQ-C30 
Arndt 
200614 
2006 Germany Prospective CRC 3 Year After 
Diagnosis 
German general 
population43 
92.1% 222 2028 Mean 66.0 ± 
9.2 
Mean 66.0 ± 
11.6 (16–92) 
52% 43.8% EORTC 
QLQ-C30 
EORTC 
QLQ-CR38 
Jansen20 2011 Germany Prospective CRC 10 Years After 
Diagnosis 
German general 
population43 
60% 117 2028 Mean 62.6 ± 
8.9  
Mean 66.0 ± 
11.6 (16–92) 
46% 43.8% EORTC 
QLQ-C30 
Kopp21 2004 Germany RCT and Cohort 
studies 
CRC After Surgery German general 
population43 
NR 325 193 Mean 68.6 
(33–92) 
Range 60–69 62.8% 100% EORTC 
QLQ-C30 
Rauch26 2004 France Cross-sectional Rectum Disease-free 
survivors and 
complete 
remission 
more than 2 
years after 
diagnosis 
German general 
population43 
Norwegian general 
population44 
78.1% 121 3993 Median 64 
(43–91) 
Norwegian: 
Mean 47.4 
(19–93) 
German: 
Mean 66.0 ± 
11.6 (16–92) 
64.5% 47.7% EORTC 
QLQ-C30 
EORTC 
QLQ-CR38 
Neuman2
2 
2007 US Retrospective Rectum After 
sphincter-pres
erving surgery 
German general 
population43 
67.4% 123 2028 Median 63.0 
(35–87) 
Mean 66.0 ± 
11.6 (16–92) 
67.5% 43.8% EORTC 
QLQ-C30 
EORTC 
QLQ-CR38 
Pucciarel 2008 Italy Retrospective Rectum After Surgery Age- and 80.7% 117 117 Median 65 NR 63.2% NR EORTC 
Table1
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        Target Population   Sample Size Age (year) Male (%)   
First 
Author 
Year of 
Publication 
Country 
of origin 
Study design of 
CRC data 
CRC Trajectory 
Stage of CRC 
Compared with Response 
rate 
CRC non-C
RC 
CRC Non-CRC CRC Non-C
RC 
HRQOL 
instrument 
li 200825 sex-matched German 
general population43 
(39–92) QLQ-C30 
EORTC 
QLQ-CR38 
Zajac35 2008 Poland Cross-sectional Rectum After Surgery German general 
population43 
NR 50 2028 Mean 62.1 
(38 to 80) 
Mean 66.0 ± 
11.6 (16–92) 
56.0% 43.8% EORTC 
QLQ-C30 
EORTC 
QLQ-CR38 
Pucciarel
li 201024 
2010 Italy Cross-sectional Rectum After 
chemo-radioth
erapy followed 
by radical 
surgery 
Age- and 
sex-matched German 
general population43 
80.2% 81 81 Median 62 
(33–81)  
NR 58.0% NR EORTC 
QLQ-C30 
EORTC 
QLQ-CR38 
Guren19 2003 Norway Prospective Rectum During 
Radiotherapy 
Norwegian general 
population44 
75.0% 42 1965 Median 67 
(38–78) 
Mean 47.4 
(19–93) 
59.5% 51.7% EORTC 
QLQ-C30 
EORTC 
QLQ-CR38 
Thong 
2011a30 
2011 Netherlan
ds 
Random sample 
survey on 
Eindhoven 
Cancer Registry 
Rectum Survivors Age- and 
sex-matched Dutch 
general population45 
62.2% 340 1731 Mean 68.2 ± 
9.6  
Mean 53 ± 
16 
66.2% 54.0% EORTC 
QLQ-CR38 
SF-36 
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        Target Population   Sample Size Age (year) Male (%)   
First 
Author 
Year of 
Publication 
Country 
of origin 
Study design of 
CRC data 
CRC Trajectory 
Stage of CRC 
Compared with Response 
rate 
CRC non-C
RC 
CRC Non-CRC CRC Non-C
RC 
HRQOL 
instrument 
Thong 
2011b29 
2011 Netherlan
ds 
Random sample 
survey on 
Eindhoven 
Cancer Registry 
Colon Survivors Age- and 
sex-matched Dutch 
general population45 
74.7% 848 1731 Mean 69.4 ± 
9.6  
Mean 53 ± 
16 
43.8% 54.0% EORTC 
QLQ-CR38 
SF-36 
Austin41 2010 Australia Cross-sectional Rectum Survivors 
After Pelvic 
Exenteration 
Australian general 
population52 
84.1% 37 3014 Median 62  
(31–85) 
Mean 45.29 
± 18.69 
43.2% 49.1% SF-36 
Domati17 2011 Italy Retrospective CRC After Surgery 
(5 years after 
the diagnosis) 
Italian general 
population49 
38.8% 220 NR Mean 66.6 
(43–81)      
  
NR 57.3% NR SF-36 
Vironen33 2006 Finland Cross-sectional Rectum After Surgery Finnish general 
population53 
87.2% 82 1440 Mean 68 Range 40-79 63.4% 43.3% SF-36 
Sapp37 2003 US Cross-sectional Female 
CRC 
Survivors US general woman 
population51 
94.9% 209 413 Mean 72 
(43–85) 
≥65 0.0% 0.0% SF-36 
Trentham
-Dietz38 
2003 US Cross-sectional Female 
CRC 
Survivors US general woman 
population51 
94.9% 209 413 Mean 72 
(43–85) 
≥65 0.0% 0.0% SF-36 
Wilson34 2006 UK Prospective CRC After Surgery UK general 
population50 
95.7% 201 NR Mean 68.2 
(36–91) 
Range 65-74 73.1% NR SF-12 
EQ-5D 
EORTC 
QLQ-C30 
FACT-C 
Running title: Quality of CRC HRQOL comparative studies 
4 
        Target Population   Sample Size Age (year) Male (%)   
First 
Author 
Year of 
Publication 
Country 
of origin 
Study design of 
CRC data 
CRC Trajectory 
Stage of CRC 
Compared with Response 
rate 
CRC non-C
RC 
CRC Non-CRC CRC Non-C
RC 
HRQOL 
instrument 
Serpentin
i27 
2011 Italy Cross-sectional Rectum Survivors Italian general 
population49 
80.7% 117 1129 Median 65 15-24 
(18.5%) 
25-44 
(35.3%) 
45-64 
(28.6%) 
≥65 (17.6%) 
63.2% 48.1% PGWBI 
Hornbroo
k39 
2011 US Cross-sectional CRC Survivors US general 
population51 
51.9% 679 NR Ostomate: 
Mean 72 ± 
10 
Nonostomate
: Mean 71 ± 
11 
NR 58.9% NR SF-6D 
Giesinger
18 
2009 Austria Cross-sectional CRC Unknown Age- and 
sex-matched Austrian 
general population46 
NR 206 206 Mean 64.8 ± 
11.5 (33–88) 
Mean 64.9 ± 
11.6 
52.9% 52.9% EORTC 
QLQ-C30 
Trninic32 2009 Bosnia 
and 
Herzegovi
na 
Cross-sectional CRC After Surgery Healthy population 76.3% 67 30 With 
colostomy:  
Mean 64 ± 
12.9 
Without 
colostomy :  
Mean 61 ± 
Mean 60 ± 
12.2 
51.7% 51.7% EORTC 
QLQ-C30 
EORTC 
QLQ-CR38 
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        Target Population   Sample Size Age (year) Male (%)   
First 
Author 
Year of 
Publication 
Country 
of origin 
Study design of 
CRC data 
CRC Trajectory 
Stage of CRC 
Compared with Response 
rate 
CRC non-C
RC 
CRC Non-CRC CRC Non-C
RC 
HRQOL 
instrument 
12.7 
Caravati-
Jouvence
aux15 
2011 France Random sample 
survey from 
three tumor 
registries in 
France 
CRC 5, 10, and 15 
Years After 
Diagnosis 
Age-, sex- and 
residence 
area-matched French 
general population 
37.2% 542 1181 Mean 70.8 Mean 70.2 56.6% 50.9% EORTC 
QLQ-C30 
SF-36 
Gall40 2007 Australia Prospective Colon After recovery 
from treatment 
Australian general 
population54 for 
SF-12 
UK general 
population for 
HADS48 
74.3% 338 NR <60 (12.7%) 
60-69 
(22.8%) 
70-79 
(43.8%) 
≥80 (20.7%) 
NR 56.0% NR SF-12 
HADS 
Reeve6 2009 US Random sample 
from Medicare 
Health 
Outcomes 
Survey 
CRC first cancer 
diagnosis 
occurred 
between their 
baseline and 
follow-up 
MHOS 
assessments 
Propensity matched 
control subjects 
without cancer 
NR 240 7160 >65  Mean 73.81 
± 6.04 
NR 55.5% SF-36 
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        Target Population   Sample Size Age (year) Male (%)   
First 
Author 
Year of 
Publication 
Country 
of origin 
Study design of 
CRC data 
CRC Trajectory 
Stage of CRC 
Compared with Response 
rate 
CRC non-C
RC 
CRC Non-CRC CRC Non-C
RC 
HRQOL 
instrument 
Den 
Oudsten1
6 
2012 Netherlan
ds 
Random sample 
survey on 
Eindhoven 
Cancer Registry 
CRC Survivors Age- and 
sex-matched Dutch 
general population45 
81.5% 1371 400 Mean 70 ± 
10 
Mean 69 ± 
10 
55.8% 56.0% EORTC 
QLQ-CR38 
Thong 
201328 
2013 Netherlan
ds 
Random sample 
survey on 
Eindhoven 
Cancer Registry 
CRC Survivors Age- and 
sex-matched Dutch 
general population45 
79.8% 3739 338 Mean 70 ± 
10 
Mean 68 ± 
11 
36.4% 55.6% HADS 
Orsini23 2013 Netherlan
ds 
Random sample 
survey on 
Eindhoven 
Cancer Registry 
Rectum Survivors Age- and 
sex-matched Dutch 
general population45 
91.7% 143 1613 Mean 64.7 ± 
10.1 
NR 62.2% NR SF-36 
EORTC 
QLQ-CR38 
Traa31 2014 Netherlan
ds 
Cross-sectional Rectum After Surgery Age- and 
sex-matched Dutch 
general population45 
85% 439 350 Mean 66.2 ± 
9.8 
Mean 66.4 ± 
10.4 
59.0% 57.1% EORTC 
QLQ-C30 
EORTC 
QLQ-CR38 
Wong42 2013 Hong 
Kong, 
China 
Cross-sectional CRC Survivors Age- and 
sex-matched Hong 
Kong general 
population55 
79.4% 381 515 Mean 64.3 ± 
11.0 
NR 54.6% NR SF-12 
FACT-C 
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        Target Population   Sample Size Age (year) Male (%)   
First 
Author 
Year of 
Publication 
Country 
of origin 
Study design of 
CRC data 
CRC Trajectory 
Stage of CRC 
Compared with Response 
rate 
CRC non-C
RC 
CRC Non-CRC CRC Non-C
RC 
HRQOL 
instrument 
Pollack36 2006 Sweden Cross-sectional Rectum After Surgery Age-matched sample 
of the Swedish 
population47 
55.2% 139 NR mean 74 NR 54.0% NR EORTC 
QLQ-C30 
Note: NR=Not reported; CRC=colorectal cancer; HRQOL=health-related quality of life; EORTC= European Organisation for Research and Treatment of Cancer; QLQ-C30=quality of life 
questionnaire core 30 module; QLQ-CR38= colorectal cancer specific quality of life questionnaire module; SF-12= 12-item Short term Health Survey; SF-36= 36-item Short term Health 
Survey; SF-6D= Short term 6-dimension Health Survey; EQ-5D= EuroQoL 5-dimension; FACT-C= Functional Assessment of Cancer Therapy-colorectal; HADS= Hospital Anxiety and 
Depression Scale; PGWBI= Psychological General Well-Being Index 
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Table 2. General characteristics and available normative data of the standardized validated HRQOL instruments identified in 31 comparative studies  
Instrument 
Target Disease 
Population Items Subscales/Domains Score 
Single Item 
Score Response Options Original language Available normative data 
Cancer-specific              
EORTC QLQ-C30 Cancer 30 9 6 4-point (28 items) 
7-point (2 global 
items) 
English German43, Norway44, 
Netherland45, Austria46, 
Sweden47, France15 
EORTC QLQ-CR38 CRC 38 9 3 4-point English Netherland45 
Non-cancer-specific        
HADS Anxiety Disorders / 
Depression 
14 2 0 4-point English for UK UK48, Netherland45 
Generic        
PGWBI General 22 6 0 6-point English for the US Italy49 
EQ-5D General 5 5 0 3-point English UK50 
SF-36 General 5 5 0 3-point (10 items) 
5-point (25 items) 
6-point (1 item) 
English for the US US51, Australia52, Finland53, 
Netherland45, France 
SF-12 General 12 8 0 3-point (2 items) 
5-point (10 items) 
English for the US UK50, Australia54, Hong 
Kong55 
SF-6D General 6 6 0 4-point (1 item) 
5-point (3 items) 
6-point (2 items) 
English US51 
Note: 
     
  
EORTC=European Organization for Research and Treatment of Cancer; QLQ=Quality-of-Life Questionnaire; SF-12= 12-item Short term Health Survey; SF-36= 36-item 
Short term Health Survey; SF-6D= Short term 6-dimension Health Survey; EQ-5D= EuroQoL 5-dimension; HADS= Hospital Anxiety and Depression Scale; PGWBI= 
Psychological General Well-Being Index 
Table2
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Table 3. Level of reporting of minimum standard checklist for evaluation of HRQOL outcomes in cancer clinical trials  
  
HRQOL Issue   Criteria for evaluating items No. (out of 31) % 
Conceptual 
      
A priori hypothesis stated  
  
Assessed if authors had a predefined PRO endpoint and/or stated expected changes due to the 
specific treatment 
1 3.2% 
Rationale for instrument reported  
 
Assessed if authors gave a rationale for using a specific PRO measure 11 35.5% 
Measurement 
      
Psychometric properties reported  
 
Assessed if a previously validated measure was used or psychometric properties were reported or 
referenced in the paper 
30 96.8% 
Cultural validity verified 
  
Assessed if the measure was validated for the specific study population 19 61.3% 
Adequacy of domains covered 
 
Assessed if the measure covered, at least, the main PRO dimensions relevant for a generic cancer 
population and/or according to the specific research question 
30 96.8% 
Methodology 
      
Instrument administration reported 
 
Assessed if authors specified who and/or in which clinical setting the PRO instrument was 
administered 
27 87.1% 
Baseline compliance reported 
 
Assessed if authors reported the number of patients providing a PRO assessment before the start of 
treatment 
27 87.1% 
Timing of assessments documented 
 
Assessed if authors specified the PRO timing of assessment during the trial 29 93.5% 
Missing data documented 
  
Assessed if authors gave some details on PRO missing data during the trial 11 35.5% 
Interpretation 
      
Clinical significance addressed 
 
This refers to the discussion of PRO data being clinically significant from a patient’s perspective 
and not simply statistically significant 
21 67.7% 
Presentation of results in general 
  
Assessed if authors discussed the PRO outcomes giving any comments regardless of the results 
(either expected or not) 
31 100.0% 
Note: HRQOL=health-related quality of life; PRO=patient-reported outcome 
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Table 4. Minimum Standard Checklist for Evaluating HRQOL Outcomes in Cancer Clinical Trials 
 
Conceptual Measurement Methodology Interpretation 
  
First Author A priori 
hypothesis 
stated 
(Yes/No/N
A) 
Rationale 
for 
instrumen
t reported 
(Yes/No) 
Psychometr
ic 
properties 
reported 
(Yes/No) 
Cultural 
validity 
verified 
(Yes/No/NA
) 
Adequac
y of 
domains 
covered 
(Yes/No) 
Instrument 
administrat
ion 
reported 
(Yes/No) 
Baseline 
compliance 
reported 
(Yes/No) 
Timing of 
assessments 
documented 
(Yes/No) 
Missing 
data 
document
ed 
(Yes/No) 
Clinical 
significance 
addressed 
(Yes/No) 
Presentati
on of 
results in 
general 
(Yes/No) 
Check
list 
Score 
Expected 
methodological 
quality 
Arndt 200413 No Yes Yes No Yes Yes Yes Yes Yes Yes Yes 9 / 11 Probably robust 
Arndt 200614 No Yes Yes No Yes Yes Yes Yes Yes Yes Yes 9 / 11 Probably robust 
Jansen20 No Yes Yes No Yes Yes Yes Yes Yes Yes Yes 9 / 11 Probably robust 
Kopp21 No No Yes No Yes No No Yes Yes Yes Yes 6 / 11 Limited 
Rauch26 No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 10 / 11 Probably robust 
Neuman22 No Yes Yes No Yes Yes Yes Yes Yes Yes Yes 9 / 11 Probably robust 
Pucciarelli 200825 No No Yes No Yes Yes Yes Yes No Yes Yes 7 / 11 Limited 
Zajac35 No No No No Yes No No Yes No Yes Yes 4 / 11 Very limited 
Pucciarelli 201024 No No Yes No Yes Yes Yes Yes No Yes Yes 7 / 11 Limited 
Guren19 No Yes Yes No Yes No Yes Yes Yes Yes Yes 8 / 11 Probably robust 
Thong 2011a30 Yes No Yes Yes Yes Yes Yes Yes No Yes Yes 9 / 11 Limited 
Thong 2011b29 No No Yes Yes Yes Yes Yes Yes No Yes Yes 8 / 11 Limited 
Austin41 No No Yes Yes Yes Yes Yes Yes No Yes Yes 8 / 11 Limited 
Domati17 No Yes Yes Yes Yes Yes Yes Yes No No Yes 8 / 11 Limited 
Vironen33 No No Yes Yes Yes Yes Yes Yes No No Yes 7 / 11 Limited 
Sapp37 No No Yes Yes Yes Yes Yes Yes No No Yes 7 / 11 Limited 
Trentham-Dietz38 No No Yes Yes Yes Yes Yes Yes No Yes Yes 8 / 11 Limited 
Wilson34 No Yes Yes Yes Yes Yes Yes Yes Yes No Yes 9 / 11 Probably robust 
Serpentini27 No Yes Yes Yes Yes Yes Yes Yes No Yes Yes 9 / 11 Limited 
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Conceptual Measurement Methodology Interpretation 
  
First Author A priori 
hypothesis 
stated 
(Yes/No/N
A) 
Rationale 
for 
instrumen
t reported 
(Yes/No) 
Psychometr
ic 
properties 
reported 
(Yes/No) 
Cultural 
validity 
verified 
(Yes/No/NA
) 
Adequac
y of 
domains 
covered 
(Yes/No) 
Instrument 
administrat
ion 
reported 
(Yes/No) 
Baseline 
compliance 
reported 
(Yes/No) 
Timing of 
assessments 
documented 
(Yes/No) 
Missing 
data 
document
ed 
(Yes/No) 
Clinical 
significance 
addressed 
(Yes/No) 
Presentati
on of 
results in 
general 
(Yes/No) 
Check
list 
Score 
Expected 
methodological 
quality 
Hornbrook39 No No Yes Yes Yes Yes Yes No No Yes Yes 7 / 11 Limited 
Giesinger18 No No Yes No Yes Yes No No No Yes Yes 5 / 11 Limited 
Trninic32 No Yes Yes No Yes No Yes Yes Yes No Yes 7 / 11 Limited 
Caravati-Jouvence
aux15 
No No Yes Yes No Yes Yes Yes No Yes Yes 
7 / 11 Limited 
Gall40 No Yes Yes Yes Yes Yes Yes Yes No No Yes 8 / 11 Limited 
Reeve6 No No Yes Yes Yes Yes No Yes No Yes Yes 7 / 11 Limited 
Den Oudsten16 No No Yes Yes Yes Yes Yes Yes Yes Yes Yes 9 / 11 Probably robust 
Thong 201328 No No Yes Yes Yes Yes Yes Yes No Yes Yes 8 / 11 Limited 
Orsini23 No No Yes Yes Yes Yes Yes Yes No No Yes 7 / 11 Limited 
Traa31 No No Yes Yes Yes Yes Yes Yes No No Yes 7 / 11 Limited 
Wong42 No No Yes Yes Yes Yes Yes Yes No No Yes 7 / 11 Limited 
Pollack36 No No Yes No Yes Yes Yes Yes Yes No Yes 7 / 11 Limited 
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Table 5. Further quality assessments of included studies 
  Comparison Group 
First Author Compare with 
their populations 
Contemporary 
comparison (Yes, 
≤5yrs; No, >5yrs) 
Source of comparison group Matched comparison 
group 
Matching criteria 
Arndt 200413 Yes Yes German general population No Nil 
Arndt 200614 Yes Yes German general population No Nil 
Jansen20 Yes No German general population No Nil 
Kopp21 Yes Yes German general population No Nil 
Rauch26 No No Norwegian and German general 
populations 
No Nil 
Neuman22 No No German general population No Nil 
Pucciarelli 200825 No No German general population Yes Age- and sex-matching 
Zajac35 No No German general population No Nil 
Pucciarelli 201024 No No German general population Yes Age- and sex-matching 
Guren19 Yes Yes Norwegian general population No Nil 
Thong 2011a30 Yes Yes Dutch general population Yes Age- and sex-matching 
Thong 2011b29 Yes Yes Dutch general population Yes Age- and sex-matching 
Austin41 Yes Yes Australian general population No Nil 
Domati17 Yes No Italian general population No Nil 
Vironen33 Yes No Finnish general population No Nil 
Sapp37 Yes Yes US woman general population No Nil 
Trentham-Dietz38 Yes Yes US woman general population No Nil 
Wilson34 Yes No UK general population No Nil 
Serpentini27 Yes No Italian general population No Nil 
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  Comparison Group 
First Author Compare with 
their populations 
Contemporary 
comparison (Yes, 
≤5yrs; No, >5yrs) 
Source of comparison group Matched comparison 
group 
Matching criteria 
Hornbrook39 Yes No US general population No Nil 
Giesinger18 Yes Yes Austrian general population Yes Age- and sex-matching 
Trninic32 Yes Yes Healthy population No Nil 
Caravati-Jouvenceaux15 Yes Yes French general population Yes Age-, sex- and residence 
area-matching 
Gall40 Yes Yes Australian general population No Nil 
Reeve6 Yes Yes Individuals without cancer Yes Propensity score matching 
Den Oudsten16 Yes Yes Dutch general population Yes Age- and sex-matching 
Thong 201328 Yes Yes Dutch general population Yes Age- and sex-matching 
Orsini23 Yes Yes Dutch general population Yes Age- and sex-matching 
Traa31 Yes Yes Dutch general population Yes Age- and sex-matching 
Wong42 Yes Yes Hong Kong general population Yes Age- and sex-matching 
Pollack36 Yes Yes Sweden general population Yes Age-matching 
 
 
 
 
Figure 1. PRISMA Flow Diagram of the literature search and selection process 
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